Abbott has announced positive results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease. The results suggest that atrasentan, used in conjunction with renin-angiotensin system (RAS) inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type 2 diabetes. Current standard of care modestly slows the progression of the disease and previous studies with standard of care have shown an association with albuminuria reduction and a slowing of disease progression.
Atrasentan is a highly selective endothelin-A receptor (ETAR) antagonist under investigation as a potential treatment for diabetic kidney disease.
The study results were published in the Journal of the American Society of Nephrology.